Please login to the form below

Not currently logged in
Email:
Password:

Benlysta

This page shows the latest Benlysta news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Lupus treatment misses mark in trial

AstraZeneca’s Lupus treatment misses mark in trial

The candidate in question operates a differently to other lupus treatments, including already approved Benlysta, GlaxoSmithKline’s subcutaneous formulation of its market-leading product. ... However, anifrolumab targets a protein that is involved in

Latest news

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    The CHMP also delivered more good news to GSK by recommending approval of the company's subcutaneous pen-injector of Benlysta (belimumab), providing a more patient-friendly alternative to the current ... Benlysta is used as an add-on treatment for adults

  • GSK and AZ drugs impress in lupus trials GSK and AZ drugs impress in lupus trials

    GSK reported new phase III data on a new subcutaneous formulation of its market-leading Benlysta (belimumab) product - which was approved as in one-hour infusion formulation for SLE in 2011, ... Benlysta sales were £166m ($251m) in the first nine months

  • Hints of recovery at GSK as group sales climb Hints of recovery at GSK as group sales climb

    Some of its newer treatments have also failed to grow as expected, with the much-hyped lupus drug Benlysta (belimumab) - the first drug approved for the condition in fifty years - failing

  • GSK starts recovery from China crisis as growth returns GSK starts recovery from China crisis as growth returns

    Other gainers included platelet-booster Promacta (eltrombopag) - up 46 per cent to £186m in 2013 - and lupus treatment Benlysta (belimumab), which more than doubled to £146m.

  • 2013 - biotech boomed 2013 - biotech boomed

    to lupus treatment Benlysta (belimumab) and the late-stage type 2 diabetes candidate albiglutide.

More from news
Approximately 4 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.

  • Opening up innovation Opening up innovation

    Leading this is Benlysta (belimumab), which in 2011 became the first new treatment for lupus to be approved in over 50 years and is being investigated for other auto antibody-dependent ... In much the same way that the last decade saw the anti-TNF

  • Building a business that is lean and specialised Building a business that is lean and specialised

    The company was Human Genome Sciences and its acquirer, GlaxoSmithKline, had its eye on gaining full control of Benlysta (belimumab), the lupus product that the two had been co-marketing.

  • Pharma deals during September 2012 Pharma deals during September 2012

    In a similar vein, Biogen Idec has sold its royalty rights to Benlysta (belimunab) for the treatment of systemic lupus erythematosus, to DRI Capital Managed Fund. ... Royalty monetisation. Benlysta (belimunab) for the treatment of systemic lupus

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... There is $150m in potential licence

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics